{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:16:09Z","timestamp":1761599769364,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.autrev.2007.02.004","type":"journal-article","created":{"date-parts":[[2007,3,8]],"date-time":"2007-03-08T07:02:48Z","timestamp":1173337368000},"page":"553-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["What is the role of rituximab in the treatment of rheumatoid arthritis?"],"prefix":"10.1016","volume":"6","author":[{"given":"Fabiola","family":"Atzeni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turiel","family":"Maurizio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2007.02.004_bib1","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B-cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2007.02.004_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2007.02.004_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [review]","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.autrev.2007.02.004_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.autrev.2007.02.004_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/ard.2005.042648","article-title":"Update on rituximab","volume":"64","author":"Eisenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.02.004_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.autrev.2006.02.007","article-title":"Treatment of rheumatoid arthritis with rituximab: an update and possible indications","volume":"5","author":"De Vita","year":"2006","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2007.02.004_bib8","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/rheumatology\/keh616","article-title":"B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?","volume":"44","author":"Panayi","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2007.02.004_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00002281-200405000-00003","article-title":"B cells as therapeutic targets for rheumatic diseases","volume":"16","author":"Looney","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2007.02.004_bib10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/art.1780240310","article-title":"Production of agglutinators and rheumatoid factors in plasma cells of rheumatoid and non rheumatoid synovial tissues","volume":"24","author":"Fehr","year":"1981","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib11","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.4049\/jimmunol.113.5.1583","article-title":"Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes","volume":"113","author":"Goldstein","year":"1974","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2007.02.004_bib12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000230171","article-title":"Studies on chemotaxis. XI. Effect on neutrophils of lysosomal and other subcellular fractions from leukocytes","volume":"35","author":"Borel","year":"1969","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.autrev.2007.02.004_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI107949","article-title":"Complement fixation by rheumatoid factor","volume":"55","author":"Tanimoto","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2007.02.004_bib14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/rheumatology\/38.11.1150","article-title":"Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma","volume":"38","author":"Protheroe","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2007.02.004_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2007.02.004_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/ard.62.suppl_2.ii55","article-title":"(anti-CD20) experience B cell therapy for rheumatoid arthritis: the rituximab","volume":"62","author":"Shaw","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.autrev.2007.02.004_bib17","doi-asserted-by":"crossref","first-page":"ii8","DOI":"10.1093\/rheumatology\/keh617","article-title":"B cells in rheumatoid arthritis: from hypothesis to the clinic","volume":"44","author":"Keystone","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2007.02.004_bib18","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Evidence for a pathogenic role of B cells","volume":"46","author":"De Vita","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"3420","key":"10.1016\/j.autrev.2007.02.004_bib20","first-page":"LB11","article-title":"Successful treatment of infliximab-refractory rheumatoid arthritis with rituximab","volume":"46","author":"Tuscano","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib21","first-page":"S197","article-title":"Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo controlled trial in patients with rheumatoid arthritis [abstract]","volume":"46","author":"Edwards","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"for the DANCER Study Group.The Efficacy and Safety of Rituximab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment: Results of a Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib23","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib24","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.22020","article-title":"Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms","volume":"54","author":"Silverman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib25","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B Cell Subsets After Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2007.02.004_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1073\/pnas.93.1.221","article-title":"Differentiation of B cells in the non lymphoid tissue of the synovial membrane of patients with rheumatoid arthritis","volume":"93","author":"Schroder","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2007.02.004_bib29","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.4049\/jimmunol.162.5.3053","article-title":"Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis","volume":"162","author":"Kim","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2007.02.004_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1749-6632.2003.tb06042.x","article-title":"Ectopic germinal center formation in rheumatoid synovitis","volume":"987","author":"Weyand","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2007.02.004_bib31","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/1529-0131(199808)41:8<1356::AID-ART4>3.0.CO;2-X","article-title":"Use of differential subtraction method to identify genes that characterize the phenotype of cultured rheumatoid arthritis synoviocytes","volume":"41","author":"Seki","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2007.02.004_bib32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI117685","article-title":"The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium","volume":"95","author":"Dechanet","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2007.02.004_bib33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.4049\/jimmunol.169.3.1277","article-title":"Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response","volume":"169","author":"Hauser","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2007.02.004_bib34","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.4049\/jimmunol.171.4.1684","article-title":"Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals","volume":"171","author":"Cassese","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2007.02.004_bib35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2004-02-0564","article-title":"Proinflammatory mediators elicit the secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases","volume":"105","author":"Scapini","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2007.02.004_bib36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2007.02.004_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2007.02.004_bib38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ajh.10043","article-title":"Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab","volume":"68","author":"Hamaki","year":"2001","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.autrev.2007.02.004_bib39","first-page":"OP0017","article-title":"Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease modifying antirheumatic drugs [abstract]","volume":"65","author":"Emery","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997207000420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997207000420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:11:26Z","timestamp":1761599486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997207000420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1568997207000420"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2007.02.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"type":"print","value":"1568-9972"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the role of rituximab in the treatment of rheumatoid arthritis?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2007.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}